SEC Form 4 · accession 0000899243-17-012254
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary Charles Robb
Officer — Chief Financial Officer
Period of report
May 4, 2017
Accepted (ET)
May 8, 2017 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 4, 2017 | P | 5,600 | $9.7479 | A | 6,858 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price for the entire number of shares purchased. The actual purchase prices range from $9.7470 to $9.7499 per share. Detailed information on the exact number of shares purchased at each purchase price can be obtained from the issuer upon request.